All In Biotech

Drug Trial Radar · NCT06016738

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Nov 16, 2023

Primary completion

Oct 31, 2026

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Olema Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Conditions

  • Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • ER Positive Breast Cancer
  • HER2 Negative Breast Carcinoma

Interventions

  • PalazestrantDrug

    Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.

  • FulvestrantDrug

    Participants will be treated with fulvestrant on C1D1, C1D15, and then on Day 1 of every subsequent 4 week (28 day) cycle

  • AnastrozoleDrug

    Participants will be treated with anastrozole once daily on a 4 week (28 day) cycle

  • LetrozoleDrug

    Participants will be treated with letrozole once daily on a 4 week (28 day) cycle

  • ExemestaneDrug

    Participants will be treated with exemestane once daily on a 4 week (28 day) cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Selection Part: Incidence of adverse eventsTime frame: From Date of Randomization up to 16 weeks
  2. Dose-Selection Part: Incidence of dose reductionTime frame: From Date of Randomization up to 16 weeks
  3. Dose-Selection Part: Incidence of drug discontinuationTime frame: From Date of Randomization up to 16 weeks
  4. Trial: Progression-Free Survival (PFS)Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)

Locations

233 sites in 26 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Tucson, Arizona

  • Clinical Trial Site

    Fountain Valley, California

  • Clinical Trial Site

    Glendale, California

  • Clinical Trial Site

    La Jolla, California

  • Clinical Trial Site

    Los Alamitos, California

  • Clinical Trial Site

    Los Angeles, California

  • Clinical Trial Site

    Whittier, California

  • Clinical Trial Site

    Aurora, Colorado

  • Clinical Trial Site

    Denver, Colorado

  • Clinical Trial Site

    Golden, Colorado

  • Clinical Trial Site

    Grand Junction, Colorado

  • Clinical Trial Site

    Danbury, Connecticut

  • Clinical Trial Site

    Newark, Delaware

  • Clinical Trials Site

    Jacksonville, Florida

  • Clinical Trial Site

    Margate, Florida

  • Clinical Trial Site

    Orlando, Florida

  • Clinical Trial Site

    Plantation, Florida

  • Clinical Trial Site

    Tamarac, Florida

  • Clinical Trial Site

    Atlanta, Georgia

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Urbana, Illinois

  • Clinical Trial Site

    Baton Rouge, Louisiana

  • Clinical Trial Site

    New Orleans, Louisiana

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Detroit, Michigan

  • Clinical Trial Site

    Saint Louis Park, Minnesota

  • Clinical Trial Site

    Woodbury, Minnesota

  • Clinical Trial Site

    Lincoln, Nebraska

  • Clinical Trial Site

    Farmington, New Mexico

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Port Jefferson Station, New York

  • Clinical Trial Site

    Dayton, Ohio

  • Clinical Trial Site

    Toledo, Ohio

  • Clinical Trial Site

    Portland, Oregon

  • Clinical Trial Site

    Sayre, Pennsylvania

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Nashville, Tennessee

Showing 40 of 233 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.